Stockscreener 앱 받기
23.88
5.43%
1.23
시간 외 거래:
23.88
전일 마감가:
$22.65
열려 있는:
$22.61
하루 거래량:
669.37K
Relative Volume:
0.91
시가총액:
$693.38M
수익:
$17.16M
순이익/손실:
$-163.62M
주가수익비율:
-3.9276
EPS:
-6.08
순현금흐름:
$-121.61M
1주 성능:
+2.75%
1개월 성능:
+9.24%
6개월 성능:
+78.74%
1년 성능:
-0.25%
1일 변동 폭
$22.43
$24.69
1주일 범위
$21.87
$24.86
52주 변동 폭
$12.21
$41.31
Anaptysbio Inc Stock (ANAB) Company Profile
명칭
Anaptysbio Inc
전화
858-362-6295
주소
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
ANAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
23.88 | 693.38M | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-12-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-07-22 | 개시 | H.C. Wainwright | Buy |
| 2024-07-19 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-04-16 | 개시 | Leerink Partners | Outperform |
| 2024-04-11 | 개시 | Wells Fargo | Overweight |
| 2024-03-12 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-02-26 | 개시 | BTIG Research | Buy |
| 2024-02-21 | 개시 | Stifel | Buy |
| 2024-02-16 | 개시 | Piper Sandler | Overweight |
| 2023-05-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-05-18 | 개시 | TD Cowen | Outperform |
| 2023-01-06 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2022-09-13 | 다운그레이드 | Truist | Buy → Hold |
| 2022-09-01 | 개시 | Raymond James | Outperform |
| 2022-03-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-06-22 | 개시 | H.C. Wainwright | Buy |
| 2021-05-21 | 개시 | UBS | Neutral |
| 2021-03-16 | 업그레이드 | Truist | Hold → Buy |
| 2021-03-09 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-03-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-02-11 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2020-10-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-10-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-11-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2019-11-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-11-08 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-11-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-21 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-12-20 | 개시 | H.C. Wainwright | Buy |
| 2018-11-21 | 개시 | JP Morgan | Overweight |
| 2018-07-19 | 개시 | Credit Suisse | Outperform |
| 2018-04-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | 재확인 | Stifel | Buy |
| 2018-03-06 | 재확인 | Stifel | Buy |
| 2018-02-15 | 재확인 | SunTrust | Buy |
| 2018-01-23 | 재확인 | Credit Suisse | Outperform |
| 2017-11-15 | 개시 | SunTrust | Buy |
| 2017-11-09 | 개시 | Jefferies | Buy |
| 2017-10-11 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Anaptysbio Inc 주식(ANAB)의 최신 뉴스
AnaptysBio, Inc. (NASDAQ:ANAB) Holdings Trimmed by Bank of America Corp DE - MarketBeat
Assenagon Asset Management S.A. Sells 89,273 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio Holds 2025 Annual Stockholders Meeting - TipRanks
FMR LLC Significantly Reduces Stake in AnaptysBio Inc - GuruFocus
Stocks With Rising Relative Price Strength: AnaptysBio - Investor's Business Daily
JPMorgan Sees AnaptysBio (ANAB) as Undervalued Due to Rosnilimab - GuruFocus
Shareholders May Be More Conservative With AnaptysBio, Inc.'s (NASDAQ:ANAB) CEO Compensation For Now - simplywall.st
New RA Drug Shown to Work, Be Safe - streetwisereports.com
AnaptysBio: Rosnilimab's RA Data Sets The Stage For Blockbuster Potential (NASDAQ:ANAB) - Seeking Alpha
ANAB Schedules June 9 Conference Call with JPMorgan | ANAB Stock News - GuruFocus
Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) Price Target at $42.38 - MarketBeat
AnaptysBio (NASDAQ:ANAB) Shares Up 9.1%Should You Buy? - MarketBeat
AnaptysBio (NASDAQ:ANAB) Trading Down 4.5%Time to Sell? - MarketBeat
AnaptysBio (NASDAQ:ANAB) Upgraded by HC Wainwright to "Buy" Rating - MarketBeat
AnaptysBio (NASDAQ:ANAB) Shares Gap UpHere's What Happened - MarketBeat
AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement (NASDAQ:ANAB) - Seeking Alpha
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
AnaptysBio, Inc. (NASDAQ:ANAB) Shares Bought by Squarepoint Ops LLC - MarketBeat
TD Cowen reiterates Buy rating on AnaptysBio stock following updated trial data - Investing.com Canada
AnaptysBio (NASDAQ:ANAB) Upgraded to “Buy” at HC Wainwright - Defense World
AnaptysBio (ANAB) Shares Drop Amid Trial Data Missteps - GuruFocus
HC Wainwright & Co. Upgrades AnaptysBio (LSE:0HFQ) - Nasdaq
J&J hurts AnaptysBio with anti-inflammatory data (ANAB:NASDAQ) - Seeking Alpha
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point - Benzinga
AnaptysBio (ANAB) Reveals Promising Phase 2b Results in Rheumato - GuruFocus
Crude Oil Falls Over 1%; ISM Services PMI Tumbles In May - Benzinga
AnaptysBio describes ‘JAK-like’ efficacy for PD-1 drug in rheumatoid arthritis - Endpoints News
H.C. Wainwright upgrades AnaptysBio stock on positive trial data By Investing.com - Investing.com Canada
Anaptys stock gains on arthritis drug data (ANAB:NASDAQ) - Seeking Alpha
AnaptysBio’s Rosnilimab Shows ‘Best-in-Disease’ Profile in Phase 2b RA Trial - Insider Monkey
Stifel analysts reiterate Buy rating for AnaptysBio stock after RA study - Investing.com UK
HC Wainwright & Co. Upgrades AnaptysBio (ANAB) - Nasdaq
AnaptysBio (ANAB) Stock Upgraded by HC Wainwright & Co. with New - GuruFocus
AnaptysBio (ANAB) Stock Upgraded by HC Wainwright & Co. with New Target Price | ANAB Stock News - GuruFocus
HC Wainwright Upgrades AnaptysBio to Buy From Neutral, $38 Price Target - marketscreener.com
Stifel Reiterates Buy Rating on AnaptysBio (ANAB) - StreetInsider
AnaptysBio (ANAB) Gets Boost from Positive Phase 2 Trial Data | ANAB Stock News - GuruFocus
AnaptysBio reports promising Phase 2b trial results for RA drug By Investing.com - Investing.com India
AnaptysBio Stock Jumps On Promising Rheumatoid Arthritis Drug Readout; Retail Traders Brace For Potential Offering - Investing.com India
Transcript : AnaptysBio, Inc.Special Call - marketscreener.com
AnaptysBio Reports Positive Phase 2b Trial Results - TipRanks
AnaptysBio Reports Durable Responses, Favorable Safety for Rosnilimab in Arthritis Trial - marketscreener.com
AnaptysBio (ANAB) Reports Promising Results for Rosnilimab in Rheumatoid Arthritis | ANAB Stock News - GuruFocus
Anaptys Announces Positive Rosnilimab Data Updated Through Six M - GuruFocus
AnaptysBio reports promising Phase 2b trial results for RA drug - Investing.com Australia
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA - marketscreener.com
New Rheumatoid Arthritis Drug Achieves JAK-Like Efficacy with Better Safety Profile in Phase 2b Trial - Stock Titan
Millennium Management LLC Sells 185,049 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
Anaptysbio Inc (ANAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Anaptysbio Inc 주식 (ANAB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| RENTON HOLLINGS | Director |
Jun 18 '25 |
Sale |
23.97 |
3,015 |
72,270 |
4,965 |
1.45%
0.86%
자본화:
|
볼륨(24시간):